At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones.
Overcoming acquired resistance to targeted therapies in lung cancer
11th December 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?